tirzepatide and dvt demonstrates cardiovascular protection in head-to-head trial with dulaglutide 🩸 March is Deep Vein

In its confirmatory trial, Leqembi was shown to reduce clinical decline in mild to moderate Alzheimers by 27%, while donanemab reduced decline in early symptomatic Alzheimers by up to 36%

Of those, more than 1,300 had pre-diabetes at the studys start and were at a higher risk for developing type 2 diabetes: a chronic condition that affects a persons ability to use insulin and keep blood sugar at normal levels

The frequency of subsequent monitoring should be individualised based on the patient's overall clinical picture, comorbidities, and concurrent medications rather than the use of Mounjaro alone

GLP-1 agonists help delay the emptying of the stomach and suppress hunger